INTRODUCTION
Seasonal and pandemic influenza A infections are among the most important cause of chronic obstructive pulmonary disease (COPD) exacerbation, hospitalization, and respiratory failure. 1 Epidemiological studies support increased influenza-associated all-cause mortality in current and former smokers compared with life-time nonsmokers. 2 The extent of lung disease is an important contributing factor for hospitalization and the need for mechanical ventilation in COPD patients, whereas failure to mount appropriate anti-viral immune responses has also been shown to have a role in poor clinical outcomes. 3, 4 Active smokers without COPD inoculated with live attenuated influenza show reduced interleukin (IL)-6, and increased viral RNA in the nasal mucosa when compared with nonsmokers, indicating that cigarette smoke may directly inhibit lung epithelial responses to influenza. 4 Despite the influx of innate and acquired immune cells to the lungs, active smokers are highly susceptible to viral and bacterial infections. 5 The adverse response to cigarette smoke may be in part, due to the excessive accumulation of particulate matter in lung macrophages and airway epithelial cells 6 that could render them ineffective against infection and the lungs more susceptible to epithelial injury. 7, 8 Therefore, although cigarette smoke could alter local innate immune responses to infection in the lungs, the effect of smoke on acquired immunity in the lung mucosa remains unknown.
Animal models of cigarette smoke-induced lung disease have shown reduced expression of interferons (IFNs) and increased IL-6 and tumor necrosis factor-a in the lungs in response to influenza infection. 9, 10 Further, enhanced lung inflammation and cytokine expression in smoke-exposed mice has shown to promote susceptibility to influenza infection. 11, 12 Several experimental models, 9, 13, 14 together with clinical studies of viral-induced COPD exacerbation 15, 16 support strong evidence for ineffective anti-viral immunity in response to cigarette smoke which can be augmented by genetic susceptibility factors. [17] [18] [19] Systemic and lung-specific cellular responses to cigarette smoke result in activation of several key innate immune cells and complement proteins that accelerate pathogenic myeloidderived dendritic cell recruitment into the lungs. [20] [21] [22] [23] Activated myeloid-derived dendritic cells promote the differentiation of Th1, Th17 cells in human emphysema 24 and chronic cigarette smoke enhances IL-17 expression in gd T cells in the lungs. 22 Cytokines (e.g., IL-17A, IFN-g, IL-1b, etc.) and chemokines such as CXCL1 (KC), CXCL8 (IL-8), CXCL9 (Mig), and CXCL10 (IP-10) have been shown to induce proteinases in the lungs that are associated with emphysema development. [25] [26] [27] We have previously shown that Il-17a deficiency attenuates, although constitutive overexpression of this cytokine exacerbates, smoke-induced emphysema. 21 Further, a significant subset of gd T cells express IL-17A and have a tropism for lung mucosa in mice exposed to smoke, whereas deficiency in gd T cells results in exaggerated lung inflammation and emphysema in mice. 21 Several cytokines and chemokines expressed by innate immune cells in chronic smoke exposure and respiratory viral infection have been shown to induce lung injury; 28 however, the role of cigarette smoke-induced recruitment of gd T cells and IL-17A expression in response to respiratory viral infection remains less clear.
Although influenza infection often causes a mild-tomoderate degree of respiratory illness in immunocompetent hosts, increased morbidity and mortality in response to acute infection in human smokers has been well documented. 29 In this study, we set out to examine the impact of chronic smoke on lung immune cells and physiological outcome following influenza infection using a well-established mouse model of smoke induced lung disease. 22 We have previously found that Th17, and gd T cells have critical roles in smoke induced lung disease, 21 therefore in this study, we examined their role in response to cigarette smoke and influenza infection. We found that mice exposed to smoke recover poorly from influenza pneumonia and fail to produce high titers of hemagglutinin (HA)-specific protective antibodies. These findings were associated with the reciprocal expression of IFN-g and IL-17A in CD4 and gd T cells in the lungs. Mice that lack gd T cells (Tcrd À / À ) exposed to smoke and influenza pneumonia showed increased mortality, indicating a protective role for gd T cells in smoke and influenza infection. Finally, we determined the mechanism for the failure of mucosal gd T cells in protective immunity in mice exposed to chronic smoke.
RESULTS
Increased morbidity in smoke-exposed mice infected with influenza A Smokers with structural lung disease are at an increased risk for hospitalization and death when infected with respiratory viruses. 16, [30] [31] [32] To determine how cigarette smoke-induced lung disease can affect acquired immune responses to influenza, we designed a preclinical model that closely emulates acute respiratory infection in smokers. Mice were exposed to three months of Smoke (Smk) or ambient air (Air), followed by primary infection with influenza A virus (H3N2; sublethal dose of 25 TCID 50 ). 33 Two days following inoculation, mice received two additional weeks of cigarette smoke prior to analysis (Supplementary Figure S1A online). Mice exposed to 12 weeks of cigarette smoke had lower weight and initially lost less body mass when compared with air exposed mice (Supplementary Figure S1B) . As expected, smoke-exposed mice infected with Influenza A (Smk/Flu), lost significantly more weight on day 10, and showed increased time to recovery from the acute infection, as measured by weight gain, when compared with mice exposed to Air and infected with the same dose of Influenza A (Air/Flu) ( Figure 1a) . Consistent with an exaggerated but ineffective immune response, bronchoalveolar lavage (BAL) fluid collected in Smk/Flutreated mice showed increased neutrophilic inflammation (Figure 1b) , and matrix metalloproteinase (MMP)2 and MMP9 secretion, and MMP12 expression compared with Air/Flu and uninfected air-or smoke-exposed groups (Supplementary Figure S2A, B) . Moreover, semiquantitative histological scoring of the lungs demonstrated more severe peri-bronchial inflammation, in the lungs of Smk/ Flu-treated mice compared with the Air/Flu group, and increased mucin production as detected by Periodic AcidSchiff staining (Figure 1c and d, and Supplementary Figure  S3 ). As mice were infected with a sublethal dose of influenza, we expected no or limited mortality after influenza infection. Instead, we observed increased mortality in Smk/Flu-treated mice with 14% (6 of 43) of the Smk/Flu-treated group died compared with 1.75% (1 of 58) of the Air/Flu group.
Whole lung mRNA expression showed significantly decreased type I IFNs and cytotoxic enzymes including Granzyme b (Gzmb) in Smk/Flu compared with Air/Flutreated group (Figure 1e) . In contrast, the concentration of three pro-inflammatory cytokines, tumor necrosis factor-a, IL-6, and KC were increased in the lungs, whereas we found relative suppression of monocyte-related factors in particular Ccl3 and Ccl4 (macrophage inflammatory protein-1a (MIP-1a) and MIP-1b), and Ccl5 (RANTES), in Smk/Flu-treated group when compared with Air/Flu-treated mice (Figure 1f ).
Reciprocal expression of type I-II IFNs and IL-17A
We next examined lung specific protective immune responses to influenza in our smoke/flu model. Comprehensive characterization of single cells isolated from lungs showed increased IL-17A, but decreased IFN-g expression in Smk/Flu mice when compared with Air/Flu (Figure 2a and Supplementary Figure S4 ). Whole lung mRNA expression showed significantly decreased type II IFNs and their associated genes including IFN-induced protein with tetra-tricopeptide repeat 3 (Ifit3), transcription factor Irf7 (Figure 2b ) that is linked to susceptibility to influenza. 34 To further characterize the cellular expression profile of IFN-g and IL-17A in the lungs, we next performed intracellular cytokine (ICC) of CD3 À and CD3 þ immune cells in whole lung, spleen, and draining lymph node.
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We found a reciprocal expression of IL-17A and IFN-g in the lung CD3 þ T cells but not spleen or lung draining lymph nodes ( Supplementary Figures S6A-F) . Further analysis of cytokine expression revealed significant changes in IL-17A and IFN-g expression in CD3
þ but not CD3 À cells in the lungs (Supplementary Figure S7) . To determine the contribution of different IL-17A expressing T cell subsets, we next used flow cytometry to assess IL-17A and IFN-g expression in gd, CD4, and CD8 T cells in each of the four experimental groups. Overall, there were no significant differences in the relative abundance of CD4, CD8, or gd T cells between Air/Flu and Smk/Flu-treated mice (Supplementary Figures S8A and B) , and gdT cells were the predominant IL-17A expressing T cells. (Supplementary Figure S8C) . However, ICC analyses of lung Relative expression of anti-viral defense granzyme b (Gzmb), and Interferon b1 (Ifn-b1) were measured using mRNA isolated from whole lung on day 14 following influenza infection. (f) Cytokines and chemokines were measured in BAL fluid (tumor necrosis factor (TNF)-a) or whole lung homogenates supernatant on day 14 following influenza infection (n ¼ 8 in each group). Results represent mean±s.e.m. Significance was determined using the Student's t-test with Bonferroni correction for multiple comparisons *Po0.05, **Po0.01.
CD3
þ T cells showed increased abundance of gd and CD4 T cells that express IL-17A in Smk and Smk/Flu compared with Air or Air/Flu mice (Figure 2c and d) . Influenza infection induced significant IFN-g production in gd, CD4, and CD8 T cells; however, this response was severely blunted in CD4 and gd T cells from smoke-exposed mice (Figure 2c and d) . Interestingly, smoke did not blunt IFN-g production by CD8 T cells (Figure 2c and d) , indicating that the phenotypic differences we observed were primarily due to the impact of smoke on CD4 and gd T cells.
As neutralizing antibodies have an important role in immune defense against influenza, 35 we next examined whether chronic cigarette smoke could adversely affect antigen-specific antibody production in our model. Total IgG and IgA concentrations in the lung homogenates of uninfected smoke-exposed mice were significantly greater than the Air control group (Figure 2e ). However, protective influenza antibody (e.g., HA-specific IgG and IgA) titers in the Smk/Flu treatment group were significantly reduced when compared with the Air/Flu group ( Figure 2f ). These data indicate that despite chronic inflammatory conditions, specific anti-viral immunity (e.g., HA-specific IgG and IgA antibodies) is compromised in mice exposed to chronic smoke.
IL-17A deficiency protects smoke-exposed mice from flu
We have previously shown that IL-17A deficient (Il-17a À / À ) mice develop attenuated lung inflammation in response to cigarette smoke and are protected against emphysema, whereas airway overexpression of IL-17A results in exaggerated responses to cigarette smoke. 21 As we detected a reciprocal relation between IL-17A and IFN-g expression in gd and CD4 T cells in the lungs of Smk/Flu-treated mice, we next sought to determine whether lack of IL-17A could protect smokeexposed mice from severe and/or ineffective immune response to acute flu infection. In contrast to wild-type (WT) animals, Smk/Flu-treated Il-17a À / À mice were phenotypically similar to air-treated mice and did not show increased weight loss, did not develop respiratory failure, and showed rapid recovery from influenza infection (Figure 3a To determine if lack of IL-17A concomitant with smoking led to recovered viral specific T-cell responses, we next examined IFN-g production in different T-cell subsets as described above. ICC analyses of lung lymphocytes from influenza-infected, smoke-or air-exposed Il-17a À / À mice showed comparable induction of IFN-g in CD4 and CD8 T cells ( Figure 3g and Supplementary Figure S9A ). In particular, gd T cells in smoke-exposed Il-17a À / À mice infected with influenza showed significantly increased IFN-g expression when compared with air exposed animals infected with influenza ( Figure 3h ). Moreover, Il-17a À / À Smk/Flutreated mice produced protective HA-specific IgG and IgA antibodies ( Figure 3i and Supplementary Figure S9B) , which is consistent with intact IFN-g producing cells in the lungs. Together these findings indicate that in the absence of systemic IL-17A, smoke-exposed mice infected with influenza can appropriately increase type I and II IFNs leading to protection from influenza.
IL-17A mediates early influenza clearance but causes excessive lung injury
To determine whether IL-17A has an important role in viral clearance, we next measured lung influenza A viral titers during peak, mid, and late viral replication phases (6, 8, and 10 days post infection, respectively). 36 At peak replication (day 6), compared with WT, Il-17a À / À Air/Flu-or WT Smk/Flutreated mice, Il-17a À / À Smk/Flu showed a 10-fold increase in viral titers, indicating IL-17A is required for early clearance of influenza in smoke-exposed mice (Figure 4a ). However, during the late viral replication phase (day 10), WT Smk/Flu-treated mice showed B100-fold higher viral titers, indicating significant failure to clear viral infection compared with WT Air/Flu-treated mice ( Figure 4a) .
All groups at peak influenza amplification time points showed a similar increase in IFN-g expression, notably however when compared with WT Air/Flu condition, we found significant increase in IL-17a concentration only in the lungs of WT mice in Smk/Flu group, indicating an inappropriate cytokine response to influenza infection (Supplementary Figure S5) . WT mice treated with Smk/Flu showed lower viral titers on day 6 when compared with Il-17a À / À group ( Figure 4a) ; however, by day 10, and despite continued exposure to cigarette smoke, influenza was not detectable in nearly half of Il-17a À / À mice (4/10), compared with only 1 out of 10 in WT mice in Smk/Flu group (Figure 4a) . We also found that by day 8, viral titers were similar between the groups, whereas lung weight and hemorrhage score were less severe in Il-17a À / À mice (Figure 4c and d) . We next measured lung weight and assigned hemorrhagic scores 37, 38 to quantify acute lung inflammation and injury using the same viral replication time points (e.g., day 6-, 8-, and 10-day) in WT and Il-17A À / À mice exposed to Air/Flu and Smk/Flu. Consistent with the notion that IL-17A induces lung damage after influenza infection, IL-17a À / À Smk/Flu-treated Figure 3 Il-17a À / À mice exposed to smoke generate protective immune response against influenza. Il-17a À / À mice were exposed to air (Air) or smoke (Smk) for three months and were infected with sub-lethal H3N2 per protocol (Supplementary Figure S1) . À / À mice as indicated before (n ¼ 6 in each group). (i) Quantification of anti-hemagglutinin (HA)-specific IgG or IgA antibody using lung homogenates in the same groups. Pooled data from two separate experiments (n ¼ 5 per group). IFN-g measured in whole lung homogenates using enzyme linked immune-spot (ELISpot) in the same group of mice (n ¼ 6 per group). Results are mean ± s.e.m. *Po0.05, **Po0.01, ***Po0.001 as determined by the Student's t-test and Bonferroni correction. mice showed significantly lower lung hemorrhage score at day-10 compared with WT mice treated the same way ( Figure  4b-d) . Further, IL-17a À / À Smk/Flu-treated mice showed significantly lower lung weight than WT mice (Figure 4d ).
Anti-IL-17A treatment attenuates lung inflammation
The above results suggested a potential role for IL-17A in limiting effective immune defense against primary influenza pneumonia. Therefore, we next examined the therapeutic effects of IL-17A inhibition in our preclinical model of smoke and influenza infection. WT mice were exposed to cigarette smoke or air for 3 months and were treated with anti-IL-17A antibody or control IgG2 every three days for 2 weeks, with the first dose given 3 days before influenza A infection (Supplementary Figure S10A) . Neutralizing anti-IL-17 antibody treatment efficiently reduced available circulating IL-17A as determined by enzyme-linked immunosorbent assay (ELISA) of serum and BAL fluid in air-and smoke-exposed mice when compared with isotype control IgG2 treatment (Supplementary Figure S10B) . Air/Flu mice treated with anti-IL-17A antibody showed significantly improved recovery (e.g., less weight loss) when compared with isotype control antibodytreated mice (Figure 5a, left panel) . Inhibition of IL-17A in Smk/Flu-treated mice did not result in improved recovery when compared with the isotype control group, indicating that downstream effects of IL-17A induction in the smoke group were not affected by late inhibition of this cytokine after infection (Figure 5a , right panel). Consistent with these observations there was a significant decrease in lung inflammatory cells in the BAL fluid (Figure 5b ), lung histology ( Figure 5c and d) , and hemorrhagic score in Air/ Flu but not Smk/Flu-treated mice with anti-IL-17A antibody (Figure 5e ). Analysis of BAL fluid also showed reduced proinflammatory chemokines in Air/Flu mice that received anti-IL-17A antibody, whereas smoke-exposed mice showed relatively similar cytokine and chemokine levels (e.g., KC, tumor necrosis factor-a, and MCP-1) (Supplementary Figure  S11A) .
We next examined the relative abundance of T cells in each group and found that in vivo IL-17A blockade in the Air/Flu group resulted in significant increase in the relative abundance of gd T cells when compared with isotype control, whereas the Smk/Flu group showed no significant changes in this cell population (Figure 5f and g ). As blocking IL-17 in smoketreated animals did not offer protection from influenza, we hypothesized that smoke altered the ability of gd T cells to produce IFN-g after viral infection. To test this, we isolated lung CD45 þ from influenza-infected mice exposed to smoke or air for 3 months. Cells were treated ex vivo with anti-IL-17A antibodies or isotype control antibodies for 24 h. Consistent with the in vivo data, inhibition of IL-17A in air but not smokeexposed mice resulted in an increase in transcriptional expression of T-bet in gd T cells, whereas no significant difference were noted in CD4 þ T cells and CD45
À T cells (Figure 5h and i and Supplementary Figures S11 B and C and Supplementary Figures S12A-G) . Together, these findings indicate that smoke-mediated induction of IL-17A is critical for effective gd T cell anti-viral IFN-g responses in the lungs.
cd T cells are required for recovery from Influenza A in smoke-exposed mice
Our findings indicate a reciprocal relation between IFN-g and IL-17A expression in recovery from acute influenza infection, whereby smoke-induced increased IL-17A expression in gd and CD4 T cells leads to reduced IFN-g and decreased survival after influenza infection. As Il-17a À / À mice exposed to smoke and influenza showed attenuated lung injury and increased IFN-g expression especially in gd T cells, we next examined the role of gd T cells in the smoke-flu model. We had previously shown that Tcrd À / À mice develop an exaggerated inflammatory phenotype when exposed to four months of smoke. 21 Consistently, we found Tcrd À / À Smk/Flu-treated mice exhibited significantly increased morbidity (as assessed by greater weight loss) (Figure 6a ) and experienced higher mortality (30% vs. 14%) when compared with WT mice treated the same way. Similar to Smk/Flu Il-17 À / À mice, Smk/Flu Tcrd À / À mice showed transient increases in viral titers at peak infection (day 6), indicating that IL-17A derived from gd T cells has a critical role in early viral containment (Figure 6b) . Despite the increase in inflammatory cells, we found decreased expression of IFN-g and its regulated genes (e.g., Irf7, Gzmb, etc.) and significant reduction of protective HA specific IgG and IgA in Smk/Flu-treated Tcrd À / À mice (Figure 7a and b) . Similarly, lung homogenates of Tcrd À / À mice contained increased inflammatory cytokines (e.g., MCP-1 and IL-6), whereas anti-viral immune responses were significantly reduced (Figure 7c) . Thus, in the context of smoke-exposed mice, lack of gd T cells limits production of IFN-g and related genes, lack of which correlates with poor survival after influenza infection.
DISCUSSION
Seasonal and pandemic influenza pneumonia account for the largest number of COPD exacerbations and hospitalizations, and are in turn, associated with increased mortality. 32 Survival after acute lung infection heavily depends on the recruitment of specialized immune cells that resolve the infection while simultaneously protecting barrier functions in the lungs. 39, 40 Specifically, eradication of acute viral infections requires the rapid induction of type I IFNs to inhibit viral replication and reduce epithelial cell injury. 8 Human respiratory epithelial cells and mice exposed to smoke fail to express protective type I IFNs in response to influenza infection, 9, 11, 40 indicating the presence of suppressive factors in the lungs that could mediate poor ARTICLES MucosalImmunology | VOLUME 11 NUMBER 3 | MAY 2018 immune responses. We found that WT mice exposed to chronic smoke developed exaggerated lung inflammation marked by enhanced IL-17A expression and respiratory failure when infected with influenza. Increased mortality and morbidity in these mice was associated with decreased type I and II IFNs expression, and reduced HA-specific antibody production that resulted in inadequate viral clearance during the late stage of influenza infection.
The primary intention of our protocol was to simulate behavior in addicted smokers who continue to smoke despite development of acute lower respiratory tract infection. Our findings (e.g., reduced anti-HA specific IgG, or IgA antibody, IFN-g, and its related chemokines) suggest that chronic smoke significantly inhibits anti-viral responses. In a model of sidestream smoke and high-dose influenza infection, lung viral clearance was shown to remain intact, although smoke-exposed mice showed increased mortality, which was associated with increased tumor necrosis factor-a, IL-6, and type 1 IFN expression. 9 Although influenza-specific memory antibody formation in response to influenza re-challenge was not altered in that model, 9 our studies reported here did not specifically examine the role of IL-17a in B-cell memory response to influenza re-infection. Whether global loss of IL-17a could provide better secondary immune response upon influenza rechallenge should be an interesting area of new investigation in the future.
Prior studies have shown that under homeostatic conditions, IL-17A has a limited role in acute influenza viral clearance, because IL-17RA deficient mice showed no defect when infected with influenza. 41 We show here that under steady state conditions, IL-17A is minimally expressed by CD4 and gd T cells in the airway mucosa, but after influenza infection, they express IFN-g. However in response to cigarette smoke, lung both gd and ab population of T cells increase IL-17 production, 24 which we show here blunts IFN-g responses after influenza infection. Notably, on day 6 post infection, we observed a transient decrease in influenza viral clearance in Il17a À / À mice; however, this difference was no longer evident by day 8 and influenza-related lung injury as measured by lung weight and hemorrhagic scores were significantly improved in smoke-exposed, infected Il-17a À / À mice. Together, these findings suggest that in this model of Smk/Flu treatment, absence of IL-17a promotes improved recovery and survival by day 14 post infection.
We and other have shown that gd T cells represent less than 5% percent of total lung leukocytes, but their relative abundance is increased in response to chronic smoke exposure. 21, 42 In influenza-infected animals, Irf7, a transcription factor that is critical for the induction of type I IFN production and recovery from primary influenza infection in humans is increased. 40 The importance of this transcription factor in protection from acute viral infection has been underscored by the discovery of compound homozygous mutations in IRF7 in a patient who developed acute respiratory failure after primary influenza infection. 34 In the context of COPD and active smoking with its associated chronic lung inflammation and loss of lung structural integrity, we found that smoke-exposed mice showed significantly reduced Irf7 expression after infection with influenza, whereas air-exposed, infected mice treated the same way showed a robust enhancement of this transcription factor. In response to chronic smoke exposure gd T cells produce increased IL-17A and lose the capacity to secrete IFN-g during Influenza A infection. IL-17 production has been shown to inhibit IFNg production by CD4 þ T cells in an autocrine manner. 43 We hypothesized that the enhanced IL-17 production after chronic smoke exposure reprogrammed gd T cells inhibiting their ability to produce IFN-g. Supporting this, IL-17A deficient mice showed intact immune response, expanded gd T cell population which retain the ability to produce IFN-g after influenza infection despite chronic exposure to smoke. We also showed that exposure to smoke consistently inhibited Irf7 expression except in mice lacking IL-17A where its expression was independent of smoke exposure, indicating the inhibitory role of IL-17A in the regulation of Irf7 and both type I and Type II IFNs.
We have shown here that inhibition of IL-17A using blocking antibodies results in increased relative abundance of gd T cells and enhanced type I IFNs production during Influenza A infection. Further, we have found that blocking IL-17A in lung CD45
þ cells can reprogram gd T cells in infected mice to increase T-bet expression. Conversely, exposure to cigarette smoke blocks this expression of T-bet. Together, these findings support a mechanism whereby chronic smoke exposure promotes persistent production of IL-17 by lung gd T cells, while simultaneously inhibiting T-bet and IFN-g expression. However, as we used lung CD45 þ cells in our in vitro assays, we speculate that inhibition of IL-17 under our culture conditions could be indirect. The exact mechanism(s) for this immune response in the lungs would be an interesting area of future investigation.
Although our studies confirm that both conventional CD4 (ab) and gd T cells predominantly express IL-17A in the lungs of mice exposed to smoke, and that these cells have nonredundant roles conferring protection against lethal Influenza A, we show here that gd T cells specifically protect against Figure 5 Interleukin (IL)-17 inhibition improves influenza recovery. Wild-type (WT) mice were exposed to air (Air) or smoke (Smk) for three months and were infected with sublethal H3N2 per protocol (Supplementary Figure S9A) . Mice were treated with anti-IL-17A or isotype control (Cntrl IgG2) 100 mg per mouse for 3 days before flu infection and continued every 3 days for 2 weeks. (a) Percent body weight changes following influenza (n ¼ 9 or 10). (b) Total BAL cell count and differential (macrophages (Mac), eosinophil (Eos), lymphocytes (Lym), and neutrophils (Neu)) in the same group of mice on day 14 following influenza infection described in a *Po0.05 (n ¼ 8 or 9 mice per group). (c) Representative hematoxylin and eosin (H&E) stain of lung tissue section 14 days after influenza A infection and pathology score. (d) **Po0.01, ***Po0.001. Scale bar, 100 mm. (e) Representative lung hemorrhage (top) and cumulative scores (bottom) in the same group of mice. (f) Representative flow cytometry, and (g) cumulative data showing relative abundance of gd, CD4, and CD8 T cells in the lungs(n ¼ 6 in each group. **Po0.01 (h) Representative, and cumulative (i) lung CD45 þ cells isolated from Air/Flu and Smk/ Flu-exposed mice as described in (b), and were cultured with anti-IL-17 antibody (30 mg ml À 1 ) or isotype control (IgG2) for 24hr. T-bet, and Rorgt expression in gd T cells were detected using flow cytometry. Results are mean ± s.e.m (n ¼ 4 per group). *Po0.05 using the Student's t-test with Bonferroni correction.
influenza pneumonia under aberrant (e.g., smoke-induced) lung inflammatory conditions. In our model, the absence of gd T cells resulted in worse outcomes in mice exposed to smoke and Influenza A as assessed by increased weight loss, mortality, lung inflammation and viral burden. We found gd T-celldeficient animals exposed to smoke had significantly compromised anti-viral immunity with reduced type I and II IFN production and failure to secrete HA specific antibody. In Figure 6 Increased mortality in Tcrd À / À mice exposed to smoke and influenza. Wild-type (WT) and Tcrd À / À mice were exposed to air (Air) or smoke (Smk) for 3 months and were infected with sub lethal H3N2 per protocol (Supplementary Figure S1A) . (a) Body weight reduction (percent change) following influenza infection (n ¼ 7 to 10 mice per group). Data (mean±s.e.m.) are representative of three independent studies using Pearson's correlation coefficient. (b) Quantification of viral load in the lung from mice (WT and Tcrd À / À mice) in Smk/Flu groups. Data are presented as mean ± s.e.m. and are representative of two independent experiments. *Po0.05. (c) Representative experiment showing total bronchoalveolar lavage (BAL) cell count and differential (macrophages (Mac), eosinophil (Eos), lymphocytes (Lym), and neutrophils (Neu)) in the same group of mice on day 14 following influenza infection described in (a) (n ¼ 4 to 8 mice per group). (d) Representative hematoxylin and eosin (H&E) stain of lung tissue section 14 days after influenza A infection and pathology score (e). Scale bars, 100 mm. **Po0.01, ***Po0.001, ****Po0.0001 (f) Representative intracellular cytokine (ICC) staining analyses of lung CD4 þ T, CD8 þ T cells gated on total lung CD3 þ lymphocytes. (g) Cumulative data interleukin (IL)-17A and interferon (IFN)-g% ICC in CD4, CD8 T-cell subsets isolated from the lungs in the same group of mice (n ¼ 3 to 6 per group). *Po0.05, **Po0.01 using the Student's t-test with Bonferroni correction for multiple comparisons. addition to their previously described role in controlling cytomegalovirus infection, 44 our findings indicate that gd T cells potentially have a critical role in recovery from influenza infection in smokers with COPD.
The protective role of gd T cells were further confirmed in our preclinical model, because deletion of this subset of T cells resulted in exaggerated lung inflammation and death in mice exposed to smoke and influenza infection. Increased lung inflammation (e.g., macrophages and neutrophils) may have a significant role in increased mortality in Tcrd À / À mice treated in Smk/Flu model, but specific contribution of ineffective innate cells was not evaluated in this study. Together, our findings suggest a model, whereby cigarette smoke induces recruitment of activated gd T cells that are biased towards IL-17A expression and fail to produce protective immunity in the context of influenza infection. In this scenario, smoke exposure promotes constitutive expression of IL-17A in gd T cells, fail to produce IFN-g expression, which is required for induction of protective HA-specific antibodies. Consistent with our findings, a critical role for gd T cells has been shown where immunodeficient mice reconstituted with human peripheral blood mononuclear cells (PMBCs) specifically expanded gd T cells in response to aminobisphosphonate pamidronate treatment and showed enhanced immunity against influenza. 45 The protective effect of pamidronate against influenza was lost in mice reconstituted with gd T cells depleted human peripheral blood mononuclear cell. 45 Smoke-induced IL-17 responses limit Th1 cell differentiation that is required for effective anti-viral protection. Mice exposed to smoke show baseline weight difference, which might, in part, account for the observation that following infection weight loss is more pronounced in the air group. The slope of average weight loss per day in flu-infected mice was similar in air or smoke-exposed group, and do not account for lack of appropriate immunological response to influenza infection. Notably, however, IL-17A-deficient mice exposed to smoke recovered faster from primary influenza infection, regained weight, and showed robust type I and II IFN responses in gd T cells following influenza infection. Highlighting the detrimental impact of IL-17 in influenza responses, neutralizing antibody to IL-17A protected air-exposed mice from primary influenza pneumonia, whereas blocking IL-17 after smoke exposure did not offer similar protection. The mechanism for the protective effects of IL-17A neutralization was in part mediated through enhanced induction of T-bet and IFN-g in gd T cells. Recovery of T-bet expression was not evident in cells from mice exposed to smoke demonstrating epigenetic changes induced by smoke that limit the immune system's ability to respond to subsequent challenges. Together, our findings highlight a novel immune mechanism underlying Quantification of anti-hemagglutinin (HA)-specific IgG or IgA antibody using lung homogenates in the same four groups. Pooled data from two separate experiments are presented as mean±s.e.m. and significance was assessed using the Student's t-test. *Po0.05, **Po0.01 (n ¼ 4 to 7 mice per group). (c) Selective cytokines and chemokines concentration was measured in lung homogenates using Multiplex assay in the same group (n ¼ 4 to 8 mice per group). *Po0.05 as determined using the Student's t-test with Bonferroni correction for multiple comparisons.
respiratory failure in smokers with COPD, and suggest that exploring natural and induced properties of gd T cells in the lungs could provide new therapeutic option to treat viral infection in smokers.
METHODS
Mice. Female WT and Tcrd À / À mice (C57BL/6 background) were originally purchased from the Jackson Laboratory (Bar Harbor, ME) and all mice used in our experiments were bred at our facilities.
Il17a
À / À mice were acquired from Dr. Chen Dong's laboratory at University of Texas M. D. Anderson Cancer Center and were backcrossed six to eight generations to C57BL/6 as we have described previously. 21 All mice were bred in the transgenic animal facility at Baylor College of Medicine. All experimental protocols used in this study were approved by the Institutional Animal Care and Use Committee of Baylor College of Medicine and followed the National Research Council Guide for the Care and Use of Laboratory Animals.
Cigarette smoke exposure. Mice were exposed to cigarette smoke as we have previously reported. 21, 23 Six-to 8-week-old female mice were exposed to active smoke from commercial cigarettes (Marlboro 100's). Exposure to 4 cigarettes (approximately 4 to 5 min per cigarette) per day, 5 days a week was carried out by intermittently forcing air (4 l min À 1 ) through the burning cigarette. Intermittent cycles were designed to mimic puffing cycles of actual human smokers and to prevent CO2-induced asphyxiation. Puffing cycles consisted of 5 s of active cigarette smoke followed by 25 s of forced air by a timercontrolled two-way valve (Humphrey, Kalamazoo, MI). Mice were given 10 min of rest between each cycle of cigarette smoke exposure. In total, mice were given 4 cigarettes each day (1 h), 5 days a week for 3 months. Specific details regarding our validated whole body smoke exposure are previously published. 22 Two days following influenza infection, mice were exposed to two cigarettes each day for two additional 12 days; mice were killed 14 days following influenza infection.
Flow cytometry and antibodies. Flow cytometry was performed with a BD LSRII (BD Biosciences, San Jose, CA), and data were analyzed with FlowJo software (Tree Star, Inc, Ashland, OR). The following mouse-specific antibodies were purchased from BD Pharmingen (San Jose, CA): phycoerythrin (PE)-conjugated anti-IL-17A (559502), allophycocyanin-conjugated anti-IFN-g (554413), Pacific Blueconjugated anti-CD3e (558214), allophycocyanin-Cy7-conjugated anti-CD8a (557654), and PE-Cy5-conjugated anti-CD4 (553050). In addition, fluorescein isothiocyanate-conjugated anti-gd T-cell receptor (11-5711-82), PE-conjugated anti-RORgt (12-6981-80), PE-conjugated anti-CD11b (12-0112-82), and allophycocyaninconjugated anti-CD11c (17-0114-82) were purchased from eBioscience (San Diego, CA). PE/Cy7-conjugated anti-Tbet (644824) from Biolegend (San Diego, CA). Goat Anti-Mouse Ig (H þ L) (1010-01), horseradish peroxidase-conjugated secondary antibodies against mouse IgG (1130-05), and IgA (1140-05) for ELISA were purchased from Southern Biotechnology (Birmingham, AL). HA Recombinant Influenza A Virus protein, Subtype H3N2(A/Aichi/2/1968), and His Tag (11707V08H50) for HA-specific ELISA were purchased from Sino Biological Inc. (Beijing, China). Anti-IL-17A (CNTO8096) and isotype control (CNTO6601) rat/murine IgG2a/kappa were provided by Janssen R&D (San Diego, CA).
Gelatin gel zymography. MMP2 and MMP9 proteins in BAL fluid were detected using gelatin zymography. 46 Briefly, 10 ml of BAL fluid was separated using 10% SDS-polyacrylamide/2% gelatin and were washed in 2.5% Triton X-100 before incubation at 37 1C in developing buffer (50 mM Tris HCL at pH 8, 5 mM CaCl 2 , and 0.02% NaN 3 ). Gels were then fixed and stained with 50% methanol and 10% acetic acid that contained 0.3% w/v Coomassie blue. MMP2 and MMP9 appear as clear bands at B68 and 102 kDa, respectively. 46 ICC staining and enzyme-linked immune-spot. Mouse lung RBCfree single-cell suspensions were stimulated with phorbol 12-myristate 13-acetate (10 ng ml À 1 ) (Sigma-Aldrich, St. Louis, MO), and ionomycin (1 mg ml À 1 ) (Sigma-Aldrich) supplemented with brefeldin A (10 mg ml À 1 ) (Sigma-Aldrich) for 6 h. Cells were fixed with BD FACS lysing solution and then stained for surface markers with anti-CD3, anti-CD4, anti-CD8, and anti-gd TCR antibodies, and then fixed with 1% paraformaldehyde, permeabilized with 0.5% saponin (Sigma), and stained with anti-IFN-g and anti-IL-17A antibodies for analysis of ICC production by flow cytometry. Enzyme-linked immune-spot assay used to detect IFN-g, IL-4, and IL-17 as we have previously described. 47 mRNA isolation and quantitative PCR. Cell pellets were treated with TRIzol (Invitrogen, Carlsbad, CA), and mRNA was extracted with chloroform (Sigma-Aldrich), precipitated in isopropanol (Sigma-Aldrich), and washed in 70% alcohol (Sigma-Aldrich). The mRNA concentration was measured using Nano-Drop 2000 (Thermo Fisher Scientific, Waltham, MA). RNA was used to prepare cDNA with the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA) and Real-time reverse-transcriptase PCR was performed using Taqman Universal PCR Master Mix with specific primers to determine relative gene expression using the ABI PerkinElmer Prism 7500 Sequence Detection System (Applied Biosystems). The following primers of the analyzed genes were all purchased from Applied Biosystems: Il17a (Mm00439619_m1), Ifng (Mm01168134_m1), Mmp9 (Mm00600164_g1), Mmp12 (Mm00500554_m1), Irf7 (Mm00516788_m1), Ifit3(Mm01704846_s1), Ifnb1(Mm00439552_s1), and Gzmb(Mm00442834_m1). All data were normalized to 18S ribosomal RNA (Hs99999901_s1) expression.
Sublethal influenza infection and anti-Il-17A blocking antibody treatment. Sex and age-matched 6-to 8-week old mice with exposed to air or smoke were given influenza A/Hong Kong/8/68 (H3N2) (A/HK/ 68) at a sublethal dose of 25 TCID 50 /mouse using aerosol administration. 48 A clinical isolate of influenza A/Hong Kong/8/68 (H3N2) (A/HK; Mouse Lung Pool) virus was stored as frozen stock (2.8 Â 10 7 TCID 50 ml À 1 ). Stock was diluted 1:1,000 in 0.05% gelatin in Eagle's minimal essential medium (Sigma-Aldrich) and animals were placed in an enclosed chamber and flu virus was aerosolized for 20 min. Viral concentration in the nebulizer before and after aerosolization and in lung homogenates was determined by hemagglutination assay of infected Madin Darby canine kidney cells. Mouse weight changes, an indication of infection severity, recovery, and survival were monitored prior to and daily for 14 days post influenza infection. Mice were killed on day 14 unless indicated.
In selected experiments, mice were treated with 100 mg/mouse anti-IL-17A (CNTO8096), or equal quantity of isotype control (CNTO6601) intraperitoneally 49 3 days before influenza A inoculation and continued every 3 days for 2 weeks as described in Supplementary  Fig S10A. Determination of lung influenza viral titer. Some mice were killed on days 6, 8, and 10 after intranasal inoculation with influenza A as we have previously reported; 33 lungs were collected and rinsed in sterile water to lyse excess red blood cells. Lungs were placed in Dulbecco's modified Eagle's medium and homogenized using a glass bead beater (Biospec Products, Bartlesville, OK). Samples were diluted in Dulbecco's modified Eagle's medium containing 0.05 % trypsin (Worthington Biochemical, Lakewood, NJ) were centrifuged for 10 min at 9,000 r.p.m. and supernatants were serially diluted in 96-well roundbottom plates (Fisher Scientific, Atlanta, GA). Samples were then transferred to 96-well round-bottom plates containing Madin Darby canine kidney cell monolayers. Lung dilutions and Madin Darby canine kidney cells were incubate for 4 days and then visualized for characteristic adherence of turkey red blood cells (Fitzgerald Industries, Concord, MA).
